\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Development and Validation of UV Spectrophotometric Estimation of Perindopril Erbumine and Indapamide in Bulk and Tablet Dosage by using Area Under Curve Method},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{1970-01-01 (revised: 01 January 1970)}
\def\TheID{\makeatother }
\def\TheDate{1970-01-01}
\title{Development and Validation of UV Spectrophotometric Estimation of Perindopril Erbumine and Indapamide in Bulk and Tablet Dosage by using Area Under Curve Method}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \affil[1]{  }

\renewcommand\Authands{ and }

\date{\small \em Received: 1 January 1970 Accepted: 1 January 1970 Published: 1 January 1970}

\maketitle


\begin{abstract}
        




\end{abstract}


\keywords{}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\begin{textblock*}{10cm}(1.05cm,3cm)
{{\textit{CrossRef DOI of original article:}} \underline{}}
\end{textblock*}\let\tabcellsep& 	 	 		 
\section[{I. INTRODUCTION}]{I. INTRODUCTION}\par
Perindopril erbumine (2S,3aS,7aS)-1 -[(S)-N-[(S) -1-carboxybutyl] alanyl] hexahydro-2-indoline carboxylic acid 1-ethyl ester, is one of the nonpeptide Angiotensin II receptor antagonists, and is used for the treatment of patients with hypertension and symptomatic heart failure \hyperref[b0]{[1,} {\ref 11,} {\ref 12]} . Indapamide3-(aminosulfonyl)-4-chloro-N-(2,3-di hidro-2-methyl-1H-indol-1-yl) benzamide, is a diuretic of the class of Benzothiadiazines. The combined oral administration of perindopril with indapamide has been found to be more effective than either of the drugs alone in the treatment of hyperten-sion \hyperref[b0]{[1,} {\ref 11,} {\ref 12]} . Structures of Perindopril erbumine and Indapamide are shown in Fig. \hyperref[fig_0]{1},2   
\section[{London Journal of Medical and Health Research}]{London Journal of Medical and Health Research} 
\section[{II MATERIALS AND METHODS}]{II MATERIALS AND METHODS} 
\section[{Apparatus and instrumentation}]{Apparatus and instrumentation}\par
A shimadzu 1800 UV/VIS double beam spectrophotometer with 1cm matched quartz cells was used for all spectral measurements. Single Pan Electronic balance (CONTECH, CA 223, India) was used for weighing purpose. Sonication of the solutions was carried out using an Ultrasonic Cleaning Bath (Spectra lab UCB 40, India). Calibrated volumetric glassware (Borosil®) was used for the validation study. 
\section[{Materials}]{Materials}\par
Reference standard of Perindopril erbumine \& Indapamide API was supplied as gift sample by Marksan Pharmaceutical Ltd., Verna, Goa. Tablet sample with label claim Perindopril Erbumine 4mg and Indapamide 1.25mg per tablet (coversyl plus tablet) were purchased from local market Mumbai. 
\section[{Method development}]{Method development} 
\section[{Preparation of standard solution}]{Preparation of standard solution}\par
The standard stock solution of Perindopril erbumine \& Indapamide was prepared by accurately weighing \& transferring, 10 mg of API to 100 ml of volumetric flask. The drug was dissolved with sonication in 50 ml of methanol and volume was made up to the mark by using methanol. Then take from that 1ml and add to 10ml volumetric flask and make up with to methanol get final standard stock solution (10µg/ml) and take 0.1ml to get 1 µg/ml and were further diluted with methanol to obtain 10-50 µg/ml Perindopril erbumine \& 1-5 µg/ml Indapamide solutions. 
\section[{Determination of Wavelength Range}]{Determination of Wavelength Range}\par
For the selection of analytical wavelength range for area under curve method, 10 µg/ml solution of Perindopril erbumine \& Indapamide were scanned in the spectrum mode from 400 nm to 200 nm against methanol as blank.\par
Wavelength range were selected around wavelength maxima 210 nm and 241 nm for Perindopril erbumine \& Indapamide respectively. Different working standards were prepared between 10-50 µg/ml and 1-5 µg/ml for Perindopril erbumine \& Indapamide respectively. Various wavelength range were tried and final wavelength range between 208-214 nm for Perindopril erbumine and 239-244nm for Indapamide were selected on the basis of linear relationship between area and corresponding concentration (Figure  {\ref 3,} {\ref 4,} {\ref 5}).  
\section[{London Journal of Medical and Health Research}]{London Journal of Medical and Health Research} 
\section[{Area under curve (Area calculation)}]{Area under curve (Area calculation)}\par
Area under curve method involves the calculation of integrated value of absorbance with respect to the wavelength between two selected wavelengths such as ?1 and ?2 representing start and end point of curve region.\par
The area under curve between ?1 and ?2 was calculated using UV probe software. In this study area were integrated between wavelength ranges from 208 to 212 nm and 239-244 nm for Perindopril Erbumine \& Indapamide respectively (Fig.  {\ref 6,} {\ref 7}).\par
Area calculation: (?+?) =  
\section[{Calibration curve for Perindopril erbumine \& Indapamide}]{Calibration curve for Perindopril erbumine \& Indapamide}\par
The dilutions were made and scanned from 400 to 200 nm and area under curve (AUC) values were integrated in the range of 208-214 nm for Perindopril Erbumine and 239-244nm for Indapamide. The calibration curve were plotted between areas under curve values against concentration (Fig.  {\ref 8,}\hyperref[fig_4]{9}). 
\section[{Fig. 8: Linearity of Perindopril Erbumine}]{Fig. 8: Linearity of Perindopril Erbumine}\par
Linearity of Indapamide 
\section[{Assay of tablet formulation}]{Assay of tablet formulation}\par
Twenty tablets each containing 4mg of Perindopril erbumine \& 1.25mg of Indapamide were weighed, crushed to powder and average weight was calculated. Powder equivalent to 10 mg of Indapamide was transferred in 100 ml of volumetric flask and further diluted to obtain 5µg/mL solution with water, subjected for UV analysis using methanol as blank. This procedure was repeated three times (Table \hyperref[tab_0]{1})  \hyperref[b8]{[9,}\hyperref[b9]{10]} .\par
The above method was validated for various parameters such as Accuracy, Linearity, Precision, Limit of detection (LOD) and Limit of Quantitation (LOQ) according to ICH guideline. 
\section[{Accuracy}]{Accuracy}\par
The accuracy for the analytical method was evaluated at three different levels and results were obtained in terms of percent recovery. Three determinations at each level were performed and \% RSD was calculated for each level.    
\section[{Precision}]{Precision}\par
The precision of an analytical procedure expresses the closeness of an agreement (degree of scatter) between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions intra-day precision was studied by integrating area of standard solution of 8µg/ml concentration at six independent series in the same day. Inter-day precision studies were performed by integrating area of standard solution of 8µg/ml concentration on three consequent days. The \%RSD Was calculated.  
\section[{Limit of Detection and Limit of Quantification}]{Limit of Detection and Limit of Quantification}\par
The Limit of Detection (LOD) is the smallest concentration of the analyte that gives the measurable response. LOD was calculated using the following formulaLOD = 3.3 ? /S\par
The Limit of Quantification (LOQ) is the smallest concentration of the analyte, which gives response that can be accurately quantified. LOQ was calculated using the following formula LOQ = 10 ?/S Where, ? is standard deviation of the response and S is the slope of the calibration curve LOD of Perindopril erbumine \& Indapamide were found to be 1.991272µg/ml \& 0.090534µg/ml respectively and LOQ of Perindopril erbumine \& Indapamide were found to be 6.034157µg/ml \& 0.274643µg/ml respectively.\par
Three sets of known concentrations were prepared and scanned. By using these spectras, regression equations were obtained. By taking average of slopes and standard deviation of y-intercept, LOD and LOQ were calculated. 
\section[{III. RESULTS AND DISCUSSION}]{III. RESULTS AND DISCUSSION}\par
The UV visible spectroscopic method for the Perindopril erbumine \& Indapamide by area under curve was found to be simple, accurate, economical and reproducible. The drug concentrations were found to be linear in the range of 10-50 µg/ml \& 1-5ug/ml and the correlation coefficient value of 0.999 \& 0.999 of London Journal of Medical and Health Research Perindopril erbumine \& Indapamide respectively, indicates that developed method was linear. . The accuracy of the method was assessed by recovery studies at three different levels i.e. 50\%, 100\%, 150\%. The values of standard deviation were satisfactory and the recovery studies were close to 100\%. The \% RSD value is ? 2 indicates the accuracy of the method. The Limit of Detection and Limit of Quantitation values were found to be within limit. The result of the analysis for pharmaceutical formulation by the developed method was consistent with the label claim, highly reproducible and reliable. The method can be used for routine quality control analysis of Perindopril erbumine \& Indapamide in bulk and pharmaceutical formulations. 
\section[{IV. CONCLUSION}]{IV. CONCLUSION}\par
The UV spectroscopic AUC method for the analysis of Perindopril erbumine \& Indapamide was found to be simple, precise, and accurate, can be used for assay of bulk drug and pharmaceutical dosage formulations.\begin{figure}[htbp]
\noindent\textbf{1}\includegraphics[]{image-2.png}
\caption{\label{fig_0}Fig 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2}\includegraphics[]{image-3.png}
\caption{\label{fig_1}Fig 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{345}\includegraphics[]{image-4.png}
\caption{\label{fig_2}Fig. 3 :Fig. 4 :Fig. 5 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{667}\includegraphics[]{image-5.png}
\caption{\label{fig_3}6 Fig. 6 :Fig. 7 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{9}\includegraphics[]{image-6.png}
\caption{\label{fig_4}Fig. 9 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{P{0.12318840579710146\textwidth}P{0.4229468599033816\textwidth}P{0.09033816425120773\textwidth}P{0.12729468599033816\textwidth}P{0.041062801932367145\textwidth}P{0.04516908212560387\textwidth}}
\tabcellsep \multicolumn{2}{l}{Label claim (mg)}\tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep \tabcellsep Drug\tabcellsep \tabcellsep \\
Sr.\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
No.\tabcellsep Perindopril\tabcellsep Indapa\tabcellsep content\tabcellsep ± SD\tabcellsep \%RSD\\
\tabcellsep Erbumine\tabcellsep mide\tabcellsep (\%)\tabcellsep \tabcellsep \\
1\tabcellsep 4\tabcellsep 1.25\tabcellsep 100.01\tabcellsep \tabcellsep \\
2\tabcellsep 4\tabcellsep 1.25\tabcellsep 98.21\tabcellsep 0.7584\tabcellsep 0.7045\\
3\tabcellsep 4\tabcellsep 1.25\tabcellsep 99.75\tabcellsep \tabcellsep \\
\tabcellsep \multicolumn{5}{l}{±SD = Standard Deviation, \% RSD = \% Relative Standard Deviation}\\
2.8 Method validation\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par
 
\caption{\label{tab_0}Table 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2} \par 
\begin{longtable}{P{0.05021097046413502\textwidth}P{0.3981012658227848\textwidth}P{0.10759493670886076\textwidth}P{0.14345991561181434\textwidth}P{0.15063291139240506\textwidth}}
\tabcellsep Level of\tabcellsep Amount\tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep \tabcellsep \%\tabcellsep \\
\tabcellsep Recovery\%\tabcellsep Present\tabcellsep \tabcellsep \% RSD\\
\tabcellsep \tabcellsep \tabcellsep Recovery\tabcellsep \\
\tabcellsep Amount\tabcellsep (?g/ml))\tabcellsep \tabcellsep \\
\tabcellsep Perindopril\tabcellsep \tabcellsep \tabcellsep \\
50\%\tabcellsep Erbumine\tabcellsep 10\tabcellsep 101.4\tabcellsep 0.7548\\
\tabcellsep Indapamide\tabcellsep 5\tabcellsep 98.86\tabcellsep 0.5514\\
\tabcellsep Perindopril\tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep 10\tabcellsep 99.38\tabcellsep 1.0125\\
100\%\tabcellsep Erbumine\tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep Indapamide\tabcellsep 5\tabcellsep 99.64\tabcellsep 0.8954\\
\tabcellsep Perindopril\tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep 10\tabcellsep 99.50\tabcellsep 0.4956\\
150\%\tabcellsep Erbumine\tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep Indapamide\tabcellsep 5\tabcellsep 99.83\tabcellsep 0.3254\end{longtable} \par
 
\caption{\label{tab_2}Table 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{3} \par 
\begin{longtable}{P{0.21478494623655914\textwidth}P{0.2010752688172043\textwidth}P{0.11881720430107526\textwidth}P{0.24677419354838712\textwidth}P{0.06854838709677419\textwidth}}
\tabcellsep \multicolumn{2}{l}{Intra day}\tabcellsep Inter-day\tabcellsep \\
Parameter\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep Perindopril\tabcellsep \tabcellsep Perindopril\tabcellsep \\
\tabcellsep \tabcellsep Indapamide\tabcellsep \multicolumn{2}{l}{Indapamide}\\
\tabcellsep erbumine\tabcellsep \tabcellsep erbumine\tabcellsep \\
Sample sol conc (ug/ml)\tabcellsep 30\tabcellsep 03\tabcellsep 30\tabcellsep 03\\
AUC (mean)\tabcellsep 0.2733\tabcellsep 0.1351\tabcellsep 0.2758\tabcellsep 0.1356\\
\%RSD\tabcellsep 1.849669\tabcellsep 0.448046\tabcellsep 1.607084\tabcellsep 1.17214\end{longtable} \par
 
\caption{\label{tab_3}Table 3 :}\end{figure}
 		 		\backmatter   			 
\subsection[{ACKNOWLEDGEMENT}]{ACKNOWLEDGEMENT}\par
The authors sincerely thanks to Sahyadri College of Pharmacy, Methwade, Sangola, Solapur, Maharashtra, India for providing experimental facilities to carry out this work. 			  			  				\begin{bibitemlist}{1}
\bibitem[Dr et al. ()]{b7}\label{b7} 	 		\textit{},  		 			Dr 		,  		 			A V Kasture 		,  		 			Dr 		,  		 			K R Mahadik 		,  		 			Dr 		,  		 			S G Wadodkar 		.  	 	 		\textit{Dr. More H.N. 12 th edn. Text book of Pharmaceutical Analysis Instrumental Methods, Nirali Publication}  		2005.  (2)  p. 174.  	 
\bibitem[Chaudhary et al. ()]{b1}\label{b1} 	 		‘Determination of Losartan Potassium and Perindopril Erbumine in Tablet Formulations by Reversed-Phase HPLC’.  		 			A B Chaudhary 		,  		 			R K Patel 		,  		 			S A Chaudhari 		.  	 	 		\textit{Int J ChemTech Res}  		2010. 2  (2)  p. .  	 
\bibitem[Bhadani1 and Sellappan ()]{b3}\label{b3} 	 		‘Development and Validation of RP-HPLC Method for Simultaneous Estimation of Perindopril Erbumine and Indapamide in Combined Dosage Form’.  		 			Shweta Bhadani1 		,  		 			Mohan Sellappan 		.  	 	 		\textit{Am. J. Pharm. Tech. Res}  		2013.  (3)  p. .  	 
\bibitem[Darshana et al. ()]{b0}\label{b0} 	 		‘Development and Validation of Spectrophotometric Method for Simultaneous Estimation of Perindopril and Indapamide in Combined Dosage Form by Absorbance Correction Method’.  		 			K Darshana 		,  		 			Chhagan N Modi 		,  		 			Patel 		.  	 	 		\textit{International Journal of PharmTech Research}  		2010. 2  (1)  p. .  	 
\bibitem[Pawar et al. ()]{b2}\label{b2} 	 		‘Development and validation of UV-spectrophotometric method for simultaneous estimation of Atenolol and Indapamide in bulk and tablet dosage form’.  		 			P V Pawar 		,  		 			P D Gaikwad 		,  		 			V H Bankar 		,  		 			S P Pawar 		.  	 	 		\textit{IJPT}  		2010. 2  (4)  p. .  	 
\bibitem[Ich ()]{b9}\label{b9} 	 		 			Q2b Ich 		.  		\textit{Validation of Analytical Procedure: Methodology. International Conference on Harmonization},  		 (Geneva)  		2005.  		 			IFPMA 		 	 
\bibitem[Babu Ganduri et al. ()]{b4}\label{b4} 	 		‘Jayachandra Reddy Peddapapireddigari and Himabindu Vurimindi, Stability indicating liquid chromatographic method for the determination of related substances of Perindopril Erbumine and Indapamide from combined tablet dosage form’.  		 			Raveendra Babu Ganduri 		,  		 			Durga Mallikarjuna 		,  		 			Rao Tippa 		.  	 	 		\textit{Int. J. Pharm. Res. Sci}  		2014.  (4)  p. .  	 
\bibitem[Bekett and Stenlake ()]{b5}\label{b5} 	 		\textit{Practical Pharmaceutical Chemistry},  		 			A H Bekett 		,  		 			J B Stenlake 		.  		2002. New Delhi: CBS Publishers and Distributors. p. .  	 
\bibitem[Dr and Shankar ()]{b6}\label{b6} 	 		\textit{Text book of Pharmaceutical Analysis, 3 rd edn. Rx Publication},  		 			Dr 		,  		 			R S Shankar 		.  		1997.  	 
\bibitem[Validation of analytical procedure: text and methodology, ICH Harmonized Tripartite Guideline, Q2 (R1) ()]{b8}\label{b8} 	 		\textit{Validation of analytical procedure: text and methodology, ICH Harmonized Tripartite Guideline, Q2 (R1)},  		2005. p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
